Role of cannabinoid receptors in inhibiting macrophage costimulatory activity

Berdyshev, 2000, Cannabinoid receptors and the regulation of immune response, Chem. Phys. Lipids, 108, 169, 10.1016/S0009-3084(00)00195-X Schatz, 1993, Δ9-Tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function, Immunopharmacology, 26, 129, 10.1016/0162-3109(93)90005-B Nakano, 1992, Modulation of interleukin 2 activity by Δ9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody, Proc. Soc. Exp. Biol. Med., 201, 165, 10.3181/00379727-201-43494C Coffey, 1996, Tetrahydrocannabinol inhibition of macrophage nitric oxide production, Biochem. Pharmacol., 52, 743, 10.1016/0006-2952(96)00356-5 Jeon, 1996, Attenuation of inducible nitric oxide synthase gene expression by Δ9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κ B/Rel activation, Mol. Pharmacol., 50, 334 Fischer-Stenger, 1993, Δ9-Tetrahydrocannabinol inhibition of tumor necrosis factor-α: suppression of post-translational events, J. Pharmacol. Exp. Ther., 267, 1558 Zheng, 1992, Inhibition by delta-9-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages, Int. J. Immunopharmacol., 14, 1445, 10.1016/0192-0561(92)90017-F Zhu, 1994, Δ9-Tetrahydrocannabinol enhances the secretion of interleukin 1 from endotoxin-stimulated macrophages, J. Pharmacol. Exp. Ther., 270, 1334 Derocq, 1995, Cannabinoids enhance human B-cell growth at low nanomolar concentrations, FEBS Lett., 369, 177, 10.1016/0014-5793(95)00746-V Klein, 1998, Cannabinoid receptors and immunity, Immunol. Today, 19, 373, 10.1016/S0167-5699(98)01300-0 Yuan, 2002, Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells, J. Neuroimmunol., 133, 124, 10.1016/S0165-5728(02)00370-3 Matusuda, 1990, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346, 561, 10.1038/346561a0 Munro, 1993, Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365, 61, 10.1038/365061a0 Valk, 1997, Anandamide, a natural ligand for the peripheral cannabinoid receptor, is a novel synergistic growth factor for hematopoietic cells, Blood, 90, 1448, 10.1182/blood.V90.4.1448 Noe, 2000, Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes, J. Neuroimmunol., 110, 161, 10.1016/S0165-5728(00)00349-0 Derocq, 1998, The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cells, FEBS Lett., 425, 419, 10.1016/S0014-5793(98)00275-0 Jan, 2002, Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity, Mol. Pharmacol., 61, 446, 10.1124/mol.61.2.446 Martin, 1991, Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs, Pharmacol. Biochem. Behav., 40, 471, 10.1016/0091-3057(91)90349-7 Thomas, 1990, Characterization of the lipophilicity of natural and synthetic analogs of Δ9-tetrahydrocannabinol and its relationship to pharmacological potency, J. Pharmacol. Exp. Ther., 255, 624 Carayon, 1998, Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation, Blood, 92, 3605, 10.1182/blood.V92.10.3605 Jbilo, 1999, Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60, FEBS Lett., 448, 273, 10.1016/S0014-5793(99)00380-4 Germain, 2002, Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells, Int. Immunopharmacol., 2, 537, 10.1016/S1567-5769(01)00200-4 Smith, 2000, Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice, J. Pharmacol. Exp. Ther., 293, 136 Gross, 2000, A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis, J. Leukoc. Biol., 67, 335, 10.1002/jlb.67.3.335 Smith, 2001, The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models, Eur. J. Pharmacol., 43, 107, 10.1016/S0014-2999(01)01477-7 Klein, 2000, Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection, J. Immunol., 164, 6461, 10.4049/jimmunol.164.12.6461 Kane, 2000, Signal transduction by the TCR for antigen, Curr. Opin. Immunol., 12, 242, 10.1016/S0952-7915(00)00083-2 Villadangos, 2000, Proteolysis in MHC class II antigen presentation: who's in charge?, Immunity, 12, 233, 10.1016/S1074-7613(00)80176-4 Lenschow, 1996, CD28/B7 system of T cell costimulation, Annu. Rev. Immunol., 14, 233, 10.1146/annurev.immunol.14.1.233 Watts, 1999, T cell co-stimulatory molecules other than CD28, Curr. Opin. Immunol., 11, 286, 10.1016/S0952-7915(99)80046-6 Janeway, 1994, Signals and signs for lymphocyte responses, Cell, 76, 275, 10.1016/0092-8674(94)90335-2 Linsley, 1993, The role of CD28 receptor during T cell responses to antigen, Annu. Rev. Immunol., 11, 191, 10.1146/annurev.iy.11.040193.001203 Clements, 1996, Δ9-Tetrahydrocannabinol selectively inhibits macrophage costimulatory activity and down-regulates heat-stable antigen expression, J. Pharmacol. Exp. Ther., 277, 1315 Clements, 1998, Delta9-tetrahydrocannabinol suppresses macrophage costimulation by decreasing heat-stable antigen expression, Int. J. Immunopharmacol., 20, 415, 10.1016/S0192-0561(98)00044-7 Buckley, 2000, Immunomodulation by cannabinoids is absent in mice deficient for the CB2 cannabinoid receptor, Eur. J. Pharmacol., 396, 141, 10.1016/S0014-2999(00)00211-9 Liu, 1992, Heat-stable antigen is a costimulatory molecule for CD4 T cell growth, J. Exp. Med., 175, 437, 10.1084/jem.175.2.437 McCoy, 1995, Δ9-Tetrahydrocannabinol modulates antigen processing by macrophages, J. Pharmacol. Exp. Ther., 273, 1216 McCoy, 1999, Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation, J. Pharmacol. Exp. Ther., 289, 1620 Buckley, 1998, Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat, Neuroscience, 82, 1131, 10.1016/S0306-4522(97)00348-5 De Bruijn, 1996, Induction of heat-stable antigen expression by phagocytosis is involved in in vitro activation of unprimed CTL by macrophages, J. Immunol., 156, 2686, 10.4049/jimmunol.156.8.2686 Carlisle, 2002, Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation, Int. Immunopharmacol., 2, 69, 10.1016/S1567-5769(01)00147-3 Landsman, 1997, SR 141716A is an inverse agonist of the human cannabinoid CB1 receptor, Eur. J. Pharmacol., 334, R1, 10.1016/S0014-2999(97)01160-6 Portier, 1999, SR144528, an antagonist for the peripheral cannabinoid receptor, behaves as an inverse agonist, J. Pharmacol. Exp. Ther., 288, 582 Rhee, 2002, SR144528 as inverse agonist of CB2 cannabinoid receptor, J. Vet. Sci., 3, 179, 10.4142/jvs.2002.3.3.179 Wiley, 2002, Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes, Chem. Phys. Lipids, 121, 57, 10.1016/S0009-3084(02)00146-9 Jarai, 1999, Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors, Proc. Natl. Acad. Sci. U. S. A., 96, 14136, 10.1073/pnas.96.24.14136 Facchinetti, 2003, Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide, Glia, 41, 161, 10.1002/glia.10177 Ding, 1993, IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression, J. Immunol., 151, 1224, 10.4049/jimmunol.151.3.1224